Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Càncer de pròstata"'
Autor:
Andrea Alegre-Martí, Alba Jiménez-Panizo, Adrián Martínez-Tébar, Coralie Poulard, M. Núria Peralta-Moreno, Montserrat Abella, Rosa Antón, Marcos Chiñas, Ulrich Eckhard, Josep M. Piulats, Ana M. Rojas, Juan Fernández-Recio, Jaime Rubio-Martínez, Muriel Le Romancer, Álvaro Aytes, Pablo Fuentes-Prior, Eva Estébanez-Perpiñá
Publikováno v:
Science Advances. 9
Mutations of the androgen receptor (AR) associated with prostate cancer and androgen insensitivity syndrome may profoundly influence its structure, protein interaction network, and binding to chromatin, resulting in altered transcription signatures a
Autor:
Marcelino Yazbek Hanna, Mark Winterbone, Shea P. O’Connell, Mireia Olivan, Rachel Hurst, Rob Mills, Colin S. Cooper, Daniel S. Brewer, Jeremy Clark
Publikováno v:
Cancers
Volume 15
Issue 3
Pages: 789
Volume 15
Issue 3
Pages: 789
There is considerable interest in urine as a non-invasive liquid biopsy to detect prostate cancer (PCa). PCa-specific transcripts such as the TMPRSS2:ERG fusion gene can be found in both urine extracellular vesicles (EVs) and urine cell-sediment (Cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7413c66be166a3e4494fbfb8f9acbbe
http://hdl.handle.net/2445/196822
http://hdl.handle.net/2445/196822
Autor:
Talens Felis, Juan Bautista
[ES] Encontrar un método no invasivo de clasificación fiable para distinguir entre pacientes con cancer de próstata e hiperplasia benigna de próstata no es una tarea trivial. El antígeno prostático específico mas utilizado presenta un au- ment
Externí odkaz:
http://hdl.handle.net/10251/190835
Autor:
Michelle C. Turner, Esther Gracia-Lavedan, Kyriaki Papantoniou, Nuria Aragonés, Gemma Castaño-Vinyals, Trinidad Dierssen-Sotos, Pilar Amiano, Eva Ardanaz, Alba Marcos-Delgado, Ana Molina-Barceló, Juan Alguacil, Yolanda Benavente, Thalia Belmonte, José J. Jiménez-Moleón, Rafael Marcos-Gragera, Beatriz Pérez, Inés Gómez-Acebo, Marina Pollán, Manolis Kogevinas
Publikováno v:
Scientifc Reports (2022) 12:21807
The study was partially funded by the ‘Accion Transversal del Cancer’, approved by the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f74689b5c37b73ce3008f8868255fa6
https://hdl.handle.net/10481/79551
https://hdl.handle.net/10481/79551
Autor:
Gavier Moreno, Luisa María
Publikováno v:
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
instname
instname
[ES] El cáncer de próstata se diagnostica tras la aparición de células tumorales en el tejido de la próstata. La media de edad de personas diagnosticadas con esta enfermedad es de entre 67-69 años, siendo la tercera localización tumoral más f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e8339ab185c02716b421f3687583e2d1
https://hdl.handle.net/10251/186931
https://hdl.handle.net/10251/186931
Autor:
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domenech, Mariona Figols, Enrique González-Billalabeitia, Daniel Jiménez Peralta, Leonardo Rodríguez-Carunchio, Samuel García-Esteve, Marta Garcia de Herreros, Maria J. Ribal, Aleix Prat, Begoña Mellado
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4757
Cancers
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Scientia
Cancers
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Scientia
Simple Summary The combination of androgen deprivation therapy (ADT) with docetaxel (DX) or/and with novel anti-androgen receptor therapies have become standards for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de97278051a48f493c71bdcd4a4908a
http://hdl.handle.net/2445/197342
http://hdl.handle.net/2445/197342
Autor:
Suárez, José Francisco, Zamora, Víctor, Garin, Olatz, Hervás, Asunción, Ponce de León, Javier, Guedea, Ferran, Vigués, Francesc, Castells, Manuel, Ferrer Santanach, Montserrat, Pont, Àngels, Pardo, Yolanda, Alonso Caballero, Jordi, Ventura i Oller, Montserrat, Gutiérrez, Cristina, Ferrer, Ferran, Boladeras, Ana, Bonet Felipe, Xavier, Ávila, Mónica, Pastor, Sergi, Bonet, Carmen, Sancho, Gemma, Palou, Joan, Paula, Belén de, Goñi, Alai, Fernández, Pablo, 1957, Herruzo, Ismael, Ramos, Alfredo, 1951, Macías, Víctor, Solé, Josep, Bonet, Marta, Mariño, Alfonso, Cabrera, Patricia, Ortiz, María José, Multicentric Spanish Group Of Clinically Localized Prostate Cancer
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
To compare the effectiveness at ten years of follow-up of radical prostatectomy, brachytherapy and external radiotherapy, in terms of overall survival, prostate cancer-specific mortality and biochemical recurrence. Cohort of men diagnosed with locali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0548398b8e95e16dadb7283750eba116
http://hdl.handle.net/2445/188945
http://hdl.handle.net/2445/188945
Publikováno v:
International Journal of Molecular Sciences. 24:5447
Reproductive dysfunction and urogenital malignancies represent a serious health concern in men. This is in part as a result of the absence of reliable non-invasive tests of diagnosis/prognosis. Optimizing diagnosis and predicting the patient’s prog
Autor:
Muhammad, Qasim, Dolors, Puigjaner, Joan, Herrero, Josep M, López, Carme, Olivé, Gerard, Fortuny, Josep, Garcia-Bennett
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Background An accurate knowledge of the relocation of prostate neoplasms during biopsy is of great importance to reduce the number of false negative results. Prostate neoplasms are visible in magnetic resonance images (MRI) but it is difficult for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c87e8d4dcdb1898fdffcbc6a370d05
http://hdl.handle.net/2445/184999
http://hdl.handle.net/2445/184999
Autor:
Jeffrey C. Goh, Jeri Kim, Haiyan Wu, Tuomo Alanko, Satoshi Fukasawa, Ahmet Sezer, Christian Heinrich Poehlein, Ranaan Berger, Se Hoon Park, Christopher J. Hoimes, Susan Feyerabend, Kristiina Ojamaa, Emmanuel S. Antonarakis, Chunde Li, Charles G. Drake, Ping Qiu, Giuseppe Procopio, Aurelius Omlin, Ronald de Wit, Marine Gross-Goupil, Johann S. de Bono, Josep M. Piulats, Ken-ichi Tabata, Ulka N. Vaishampayan
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Clinical Oncology, 38, 395-405. American Society of Clinical Oncology
Universidad de Barcelona
Journal of Clinical Oncology, 38, 395-405. American Society of Clinical Oncology
PURPOSE Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)–positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and safety of pembrolizumab in three